OxThera is a biopharmaceutical company based out of Stockholm, Sweden, working to improve the lives of those with Primary Hyperoxaluria (PH). Our experimental drug, Oxabact®, is not yet approved, but has Orphan Drug designations in both the United States and Europe in treating the disease PH. We are performing a clinical trial, ePHex, to study the long-term efficacy and safety of our drug, Oxabact®, in those with Primary Hyperoxaluria (PH). Patients may be eligible if they have been diagnosed with PH, and meet the kidney function and plasma oxalate criteria.

Qualified patients willing to participate will undergo a 52-week study.

For more information, please visit:

https://clinicaltrials.gov/ct2/show/NCT03116685